1,000 SMA patients enrolled in landmark Real-World data study
NCT ID NCT07231549
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 1,000 people with spinal muscular atrophy (SMA) in Spain over many years. Researchers will collect information on motor skills, breathing support, and feeding needs during routine clinic visits. The goal is to standardize how SMA data is gathered in real-world settings, which could improve care and future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide a clearer picture of how spinal muscular atrophy progresses over time in routine care, helping to improve future treatment guidelines.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results depend on consistent data collection across many hospitals, which can be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hospital Sant Joan de Déu
RECRUITINGEsplugues de Llobregat, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can gene therapy help babies with SMA reach milestones? a Real-World review
- School transitions put to the test for children with a rare muscle disease
- Horseback therapy may boost movement and breathing in kids with Muscle-Weakening disease
- Newborn screening study aims to catch rare diseases at birth
- Gene therapy trial aims to halt Muscle-Wasting disease
- Higher dose of spinraza tested in SMA patients who already tried risdiplam